"A joint U.S. and Canadian team of researchers say they have confirmed how specific immune cells serve as a protected reservoir of HIV, despite potent antiretroviral (ARV) therapy. They also offer ideas for eradicating that sanctuary of cells—and the virus along with it—in a study published online June 21 in Nature Medicine."
Read more in POZ, June 22, 2009.
1 comments:
Observational HIV Study
The following is the conclusion of the Observational Study of HIV patients using CHD-FA as active ingredient:
◦It can therefore be concluded that The Product is well tolerated in patients suffering from HIV.
◦The Product caused no liver or renal toxicity in these patients.
◦The Product caused a statistically significant reduction of the viral loads of the pre-ART HIV positive patients. This effect needs further extrapolation in a randomized, double blind, controlled study.
◦The pre- ART HIV patients on The Product reported a significant improvement of their well being proving the HA hypothesis that The Product does improve health related outcomes in patients with HIV.
◦This study therefore supports further investigations into these effects in a more robust and interventional manner in order to test the validity of The Product as a possible complementary product to boost well being in HIV patients
Secomet
Read more: http://fulhold.com/pics/observational_HIV_study.pdf
Post a Comment